Daniel Cottam1, Mitchell Roslin2, Paul Enochs3, Matthew Metz4, Dana Portenier5, Dennis Smith6. 1. Bariatric Medicine Institute, 1046 E 100 S, Salt Lake City, UT, 84102, USA. drdanielcottam@yahoo.com. 2. Lenox Hill Hospital, New York, NY, USA. 3. Bariatric Specialists of North Carolina, Cary, NC, USA. 4. Rose Medical Center, Denver, CO, USA. 5. Duke Clinic, Durham, NC, USA. 6. WellStar Medical Group Comprehensive Bariatric Services, Marietta, GA, USA.
Abstract
INTRODUCTION: Single-anastomosis duodenal switch has been suggested to be an effective bariatric procedure that offers excellent weight loss and by lengthening the common channel the potential to reduce micronutrient deficiencies. PURPOSE: To evaluate the weight loss, comorbidity resolution and the 1-year nutritional outcomes of the single-anastomosis duodenal switch (SADS) procedure. SETTING: Multiple US Hospitals. METHODS: From October 2014 to January 2017, 120 patients were enrolled at six sites across the USA and underwent the SADS procedure. Weight loss, comorbidities, quality of life, and adverse events were followed post-procedure for 12 months. RESULTS: At 1, 6, and 12 months, 98.3%, 85.5%, and 77.1% of the patients were available for assessment, respectively. At 12 months, patients showed significantly reduced body mass index when compared to baseline (46.8 ± 5.8 vs 29.8 ± 4.4, P < 0.001 respectively). Sixty-five patients had type 2 diabetes at baseline; however, 11 patients lost to follow-up. Of the available data (54 patients), 96.3% of the patients had a resolution of type 2 diabetes by 12 months with a mean A1C reduction from 7.8 ± 1.6 to 5.3 ± 0.7. Additionally, there were reductions in hyperlipidemia, sleep apnea, and hypertension at 12 months. Patient gastroesophageal reflux disease satisfaction and quality of life (SF-36) scores were significantly higher at 12 months post-procedure (P < 0.001 in all cases) while 12-month protein levels remained at normal values. There were abnormalities of parathyroid hormone and vitamin D at 1 year with all other nutritional markers being not significantly different at 1 year from baseline. There were 10, IIIb, or greater complications according to the Clavien-Dindo scoring system during the study period, not all of which were related to the surgery. CONCLUSIONS: SADS is a highly efficacious weight loss procedure with significant comorbidity reduction at 1 year. At 1 year, complications and vitamin and mineral deficits appear to be consistent with other malabsorption operations. Long-term follow-up is needed, especially around complications and vitamin deficiencies.
INTRODUCTION: Single-anastomosis duodenal switch has been suggested to be an effective bariatric procedure that offers excellent weight loss and by lengthening the common channel the potential to reduce micronutrient deficiencies. PURPOSE: To evaluate the weight loss, comorbidity resolution and the 1-year nutritional outcomes of the single-anastomosis duodenal switch (SADS) procedure. SETTING: Multiple US Hospitals. METHODS: From October 2014 to January 2017, 120 patients were enrolled at six sites across the USA and underwent the SADS procedure. Weight loss, comorbidities, quality of life, and adverse events were followed post-procedure for 12 months. RESULTS: At 1, 6, and 12 months, 98.3%, 85.5%, and 77.1% of the patients were available for assessment, respectively. At 12 months, patients showed significantly reduced body mass index when compared to baseline (46.8 ± 5.8 vs 29.8 ± 4.4, P < 0.001 respectively). Sixty-five patients had type 2 diabetes at baseline; however, 11 patients lost to follow-up. Of the available data (54 patients), 96.3% of the patients had a resolution of type 2 diabetes by 12 months with a mean A1C reduction from 7.8 ± 1.6 to 5.3 ± 0.7. Additionally, there were reductions in hyperlipidemia, sleep apnea, and hypertension at 12 months. Patientgastroesophageal reflux disease satisfaction and quality of life (SF-36) scores were significantly higher at 12 months post-procedure (P < 0.001 in all cases) while 12-month protein levels remained at normal values. There were abnormalities of parathyroid hormone and vitamin D at 1 year with all other nutritional markers being not significantly different at 1 year from baseline. There were 10, IIIb, or greater complications according to the Clavien-Dindo scoring system during the study period, not all of which were related to the surgery. CONCLUSIONS: SADS is a highly efficacious weight loss procedure with significant comorbidity reduction at 1 year. At 1 year, complications and vitamin and mineral deficits appear to be consistent with other malabsorption operations. Long-term follow-up is needed, especially around complications and vitamin deficiencies.
Authors: Jason M Johnson; James W Maher; Eric J DeMaria; Robert W Downs; Luke G Wolfe; John M Kellum Journal: Ann Surg Date: 2006-05 Impact factor: 12.969
Authors: Jason M Johnson; James W Maher; Isaac Samuel; Deborah Heitshusen; Cornelius Doherty; Robert W Downs Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: Judy Jin; Ann V Robinson; Peter T Hallowell; John J Jasper; Thomas A Stellato; Scott M Wilhem Journal: Surgery Date: 2007-12 Impact factor: 3.982
Authors: Brian Mitzman; Daniel Cottam; Richie Goriparthi; Samuel Cottam; Hinali Zaveri; Amit Surve; Mitchell S Roslin Journal: Obes Surg Date: 2016-09 Impact factor: 4.129
Authors: Wendy A Brown; Guillermo Ponce de Leon Ballesteros; Geraldine Ooi; Kelvin Higa; Jacques Himpens; Antonio Torres; Scott Shikora; Lilian Kow; Miguel F Herrera Journal: Obes Surg Date: 2021-01-06 Impact factor: 4.129
Authors: Romulo P Lind; Muhammad Ghanem; Andre F Teixeira; Muhammad A Jawad; Javier Osorio; Claudio Lazzara; Lucia Sobrino; David Ortiz-Ciruela; Amador Garcia Ruiz de Gordejuela Journal: Obes Surg Date: 2022-10-24 Impact factor: 3.479